Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the best low priced biotech stocks to invest in. On April 13, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that the first patient had been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer. The company stated that the Phase 1 trial measures the safety and efficacy of VIR-5500 monotherapy in late-line mCRPC, and of VIR-5500 in combination with an androgen receptor pathway inhibitor (ARPI) in early-line mCRPC and mHSPC.
Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology, Inc. (NASDAQ:VIR), stated that the initiation of the VIR-5500 expansion cohorts highlights the considerable momentum behind the program and the enthusiasm seen across the clinical community. De Backer further stated that the company is encouraged by the promising anti-tumor activity shown in the Phase 1 data announced earlier this year and is looking forward to collaborating with Astellas after closing of the transaction to explore VIR-5500’s potential to make a meaningful difference across the spectrum of metastatic prostate cancer.
Vir Biotechnology, Inc. (NASDAQ:VIR) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies for the treatment and prevention of serious infectious diseases.
While we acknowledge the potential of VIR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Leave a comment